Presentation is loading. Please wait.

Presentation is loading. Please wait.

Insights of the RE-LY CHA 2 DS 2 -VASc subgroup analysis Hisao Ogawa Kumamoto University, Japan.

Similar presentations


Presentation on theme: "Insights of the RE-LY CHA 2 DS 2 -VASc subgroup analysis Hisao Ogawa Kumamoto University, Japan."— Presentation transcript:

1 Insights of the RE-LY CHA 2 DS 2 -VASc subgroup analysis Hisao Ogawa Kumamoto University, Japan

2 CHA 2 DS 2 -VASc Lip GY, et al., Chest 137, 263-272, 2010 maximum score is 9 since age may contrubute 0, 1, or 2 points

3 CHA 2 DS 2 -VASc – overall event rates %/year CHA 2 DS 2 -VASc 0-1 634 2 3408 3 5365 4 4378 5 2566 6 1185 7 451 8-9 125 No of patients Stroke and systemic embolism 0 1 2 3 4 5 6

4 CHA 2 DS 2 -VASc – overall event rates Major (including intracranial) bleeding CHA 2 DS 2 -VASc 0-1 634 2 3408 3 5365 4 4378 5 2566 6 1185 7 451 8-9 125 No of patients 0 1 2 3 4 5 6 7 8 %/year Major Intracranial

5 Singer DE, et al. : Ann Intern Med. 151, 297-305, 2009 Better with Warfarin -0.500.511.522.533.5 Worse with Warfarin 4-6 3 2 1 0 CHADS 2 score 2.22 0.583.75 2.07 1.212.79 0.97 0.431.41 0.19 -0.270.45 -0.11 -0.44-0.20 The Net Clinical Benefit of warfarin by CHADS 2 score

6 D110D150Warfarin D110 BID vs. warfarin D150 BID vs. warfarin CHA 2 DS 2 -VASc 0.501.001.50 Dabigatran better Warfarin better Annual rate, % 0.501.001.50 Dabigatran better Warfarin better Stroke and systemic embolism (SE) ≤2 3 4 5-9 0.9 0.5 0.8 1.3 0.8 1.4 1.6 1.0 2.0 2.4 2.1 2.8 p(inter)=0.81 p(inter)=0.60

7 0.501.001.50 Dabigatran better Warfarin better 0.501.001.50 Dabigatran better Warfarin better D110 BID vs. warfarin D150 BID vs. warfarin Intracranial bleeding D110D150Warfarin Annual rate, % ≤2 3 4 5-9 p(inter)=0.77 p(inter)=0.09 0.150.110.38 0.160.320.76 0.290.211.04 0.320.630.84 CHA 2 DS 2 -VASc

8 Conclusion  Increasing CHA 2 DS 2 -VASc scores are associated with raised risks for stroke and bleeding,  Irrespective of CHA 2 DS 2 -VASc scores dabigatran 150 mg was superior and dabigatran 110 mg non-inferior to warfarin for stroke prevention  Both dabigatran doses reduce intracranial bleeding irrespective of CHA 2 DS 2 -VASc scores Dabigatran has a favorable benefit risk profile compared to warfarin in patients with low to high CHA 2 DS 2 -VASc scores


Download ppt "Insights of the RE-LY CHA 2 DS 2 -VASc subgroup analysis Hisao Ogawa Kumamoto University, Japan."

Similar presentations


Ads by Google